Grants Funded
Grant applicants for the 2024 cycle requested a total of nearly $3 million dollars. The PSF Study Section Subcommittees of Basic & Translational Research and Clinical Research evaluated more than 100 grant applications on the following topics:
The PSF awarded research grants totaling over $650,000 dollars to support more than 20 plastic surgery research proposals.
ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.
Research Abstracts
Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.
Fat Grafting to Enhance Nerve Regeneration After Delayed Nerve Repair
Stephen Kemp PhD
2020
The Regents of the University of Michigan
ASPN/PSF Research Grant
Peripheral Nerve, Fat Grafting
Project Summary: Despite the advancement of microsurgical techniques, complete recovery of sensory and motor functions is rarely attainable. Sub-optimal results are especially noticeable for delayed, or proximal nerve injury repairs, which require regenerating nerves to travel longer distances to reach their target organs. In these circumstances, denervated Schwann cells (SC) gradually undergo senescence and atrophy, resulting in reduced secretion of neurotrophic factors and disruption of bands of Bungner. Adipose-derived stem cells (ASC) may potentially enhance nerve regeneration due to their ease of harvest, ability to secrete neurotrophic factors, and differentiate into SCs phenotypes. However, clinical utilization of purified or manipulated ASCs is highly restricted by the FDA. A work-around this constraint is the employment of autologous unpurified fat grafts, whose native ASCs may benefit nerve regeneration without regulatory burdens. The long-term goal of this research is to improve nerve regeneration and functional outcomes in delayed nerve repair and proximal nerve injuries. Our overall objective is to supplement regenerating axons and senescent SCs with multipotent stem cells naturally found in autologous unpurified fat, whose harvest and use is translatable to current clinical settings. The central hypothesis is that ASCs contained in lipoaspirate can differentiate into SCs phenotypes, and provide structural and trophic support for growing, regenerating nerves. By using autologous unpurified adipose tissue, any potential regulatory and scaling issues can be avoided. Persuaded by strong preliminary animal data in our laboratory, this hypothesis will be tested by the following specific aims: 1) Use of unpurified fat grafts to enhance nerve regeneration in both chronic denervation and chronic axotomy rat models, and, 2) Bridging a nerve gap with nerve autografts augmented with autologous unpurified fat to improve regeneration and functional outcomes. In Specific Aim 1, unpurified autologous fat grafts will separately determine SCs or motorneuron function. In Specific Aim 2, the use of unpurified fat grafts will be assessed for a surgically relevant delayed nerve repair procedure. This study is innovative since it departs from the status quo by proposing a novel, yet accessible intervention to address a clinical challenge; it is significant because the results are expected to advance current surgical standards for proximal nerve injury or delayed repair. Impact Statement: Despite the innate capacity of injured peripheral nerves to regenerate, functional recovery is dismal after delayed repair or when proximal nerve trunks are injured. Adipose-derived stem cells (ASC) may potentially enhance nerve regeneration due to their ease of harvest, ability to secrete neurotrophic factors, and differentiate into Schwann cells phenotypes. However, clinical utilization of purified ASC is highly restricted by the FDA. This constraint may be avoided by employment of autologous unpurified fat grafts, whose native ASCs may benefit nerve regeneration. The proposed study is easily translatable to the clinical setting, requires no FDA approval, and could lead to enhanced functional recovery, increased quality of life, and decreased burdens for patients with nerve injuries.
